Publication:
Navigating Non-Response: Prognosis and Strategies in Chronic Spontaneous Urticaria Management

Simple item page
dc.contributor.authorKocaturk Goncu, Emek Ozgur
dc.contributor.authorZuberbier, Thorsten
dc.contributor.institutionKocaturk Goncu, Emek Ozgur, Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany, Department of Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany, Department of Dermatology, Bahçeşehir Üniversitesi, Istanbul, Turkey
dc.contributor.institutionZuberbier, Thorsten, Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany, Department of Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany
dc.date.accessioned2025-10-05T14:33:24Z
dc.date.issued2025
dc.description.abstract[No abstract available]
dc.identifier.doi10.1111/ijd.17653
dc.identifier.endpage228
dc.identifier.issn13654632
dc.identifier.issn00119059
dc.identifier.issue2
dc.identifier.pubmed39783877
dc.identifier.scopus2-s2.0-85214406941
dc.identifier.startpage227
dc.identifier.urihttps://doi.org/10.1111/ijd.17653
dc.identifier.urihttps://hdl.handle.net/20.500.14719/6502
dc.identifier.volume64
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.oastatusAll Open Access
dc.relation.oastatusGreen Accepted Open Access
dc.relation.oastatusGreen Open Access
dc.relation.oastatusHybrid Gold Open Access
dc.relation.sourceInternational Journal of Dermatology
dc.subject.authorkeywordsAngioedema
dc.subject.authorkeywordsInflammatory Diseases
dc.subject.authorkeywordsTreatment
dc.subject.authorkeywordsUrticaria
dc.subject.authorkeywordsBarzolvolimab
dc.subject.authorkeywordsCyclosporine
dc.subject.authorkeywordsDupilumab
dc.subject.authorkeywordsImmunoglobulin E
dc.subject.authorkeywordsOmalizumab
dc.subject.authorkeywordsRemibrutinib
dc.subject.authorkeywordsBarzolvolimab
dc.subject.authorkeywordsCorticosteroid
dc.subject.authorkeywordsCyclosporine
dc.subject.authorkeywordsDupilumab
dc.subject.authorkeywordsImmunoglobulin E
dc.subject.authorkeywordsImmunosuppressive Agent
dc.subject.authorkeywordsOmalizumab
dc.subject.authorkeywordsRemibrutinib
dc.subject.authorkeywordsAdverse Event
dc.subject.authorkeywordsChronic Spontaneous Urticaria
dc.subject.authorkeywordsClinical Practice
dc.subject.authorkeywordsDisease Control
dc.subject.authorkeywordsDisease Duration
dc.subject.authorkeywordsEarly Diagnosis
dc.subject.authorkeywordsEosinophil Count
dc.subject.authorkeywordsFollow Up
dc.subject.authorkeywordsHealth Care System
dc.subject.authorkeywordsHuman
dc.subject.authorkeywordsNote
dc.subject.authorkeywordsPrognosis
dc.subject.authorkeywordsTreatment Response
dc.subject.authorkeywordsUrticaria
dc.subject.authorkeywordsAdult
dc.subject.authorkeywordsAngioneurotic Edema
dc.subject.authorkeywordsArticle
dc.subject.authorkeywordsDiagnosis
dc.subject.authorkeywordsDrug Therapy
dc.subject.authorkeywordsInflammatory Disease
dc.subject.authorkeywordsMajor Clinical Study
dc.subject.indexkeywordsbarzolvolimab
dc.subject.indexkeywordscorticosteroid
dc.subject.indexkeywordscyclosporine
dc.subject.indexkeywordsdupilumab
dc.subject.indexkeywordsimmunoglobulin E
dc.subject.indexkeywordsimmunosuppressive agent
dc.subject.indexkeywordsomalizumab
dc.subject.indexkeywordsremibrutinib
dc.subject.indexkeywordsadverse event
dc.subject.indexkeywordschronic spontaneous urticaria
dc.subject.indexkeywordsclinical practice
dc.subject.indexkeywordsdisease control
dc.subject.indexkeywordsdisease duration
dc.subject.indexkeywordsearly diagnosis
dc.subject.indexkeywordseosinophil count
dc.subject.indexkeywordsfollow up
dc.subject.indexkeywordshealth care system
dc.subject.indexkeywordshuman
dc.subject.indexkeywordsNote
dc.subject.indexkeywordsprognosis
dc.subject.indexkeywordstreatment response
dc.subject.indexkeywordsurticaria
dc.subject.indexkeywordsadult
dc.subject.indexkeywordsangioneurotic edema
dc.subject.indexkeywordsarticle
dc.subject.indexkeywordsdiagnosis
dc.subject.indexkeywordsdrug therapy
dc.subject.indexkeywordsinflammatory disease
dc.subject.indexkeywordsmajor clinical study
dc.titleNavigating Non-Response: Prognosis and Strategies in Chronic Spontaneous Urticaria Management
dc.typeNote
dcterms.referencesWatanabe, Haruka, Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab, International Journal of Dermatology, 64, 2, pp. 349-358, (2025), Zuberbier, Thorsten, The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria, Allergy: European Journal of Allergy and Clinical Immunology, 77, 3, pp. 734-766, (2022), Kaplan, Allen Phillip, Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria, Journal of Allergy and Clinical Immunology, 137, 2, pp. 474-481, (2016), Ornek, Sinem Ayse, Angioedema Indicates a Different Endotype of Chronic Spontaneous Urticaria, Asthma Allergy Immunology, 20, 2, pp. 107-113, (2022), Kocaturk Goncu, Emek Ozgur, Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria, World Allergy Organization Journal, 12, 1, (2019)
dspace.entity.typePublication
local.indexed.atScopus
person.identifier.scopus-author-id18437291300
person.identifier.scopus-author-id7004554588

Files

Collections

Scopus İndeksli Yayınlar Koleksiyonu